Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$BNGO Q4 '24 Earnings Results & Recap Bionano Genomics reported Q4 2024 EPS of -$5.90 meeting estimates, while revenue of $8.2M exceeded estimates of $6M. The company projects flattish revenue growth for 2025, in the range of $29 million to $32 million, primarily driven by a core group of routine users.
1
1
1

Since Post

Full Details
DNA2RNA2Protein
symbol logo$BNGO Q4 & FY2024 Results: 🚨 Only 3 OGM systems installed in Q4 2024 → That’s an 88% collapse vs. 25 in Q4 2023 → Conveniently not mentioned anywhere in the report 🤫 📉 Full-year installs down 48% → 86 in 2023 → only 45 in 2024 → Yet Erik Holmlin spins this as a “14% increase in installed base”… classic misdirection tactic by using a cumulative tally 💣 2025 outlook? Just 15 to 20 installs! → That’s a 81% to 75% decline from the 3-year average of ~80 installs/year → For a full year?! Pathetic. 💰 FY Revenue down 15% → $36.1M (2023) → $30.8M (2024) → Product revenue flat, instrument sales down nearly $2M despite the Stratys launch a year ago 📉 GAAP Gross Margin collapsed to 1% → From 26% in 2023 → They’re giving product away just to prop up volume ⚠️ Cash nearly gone → $20.9M reported, but only $9.5M is unrestricted 🧪 Flowcell usage per system is declining → More systems out there, but fewer tests run per system = fading demand
1
1
3

Advertisement|Remove ads.